Imprese · 27/08/20011 min di lettura
Clinical Studies of Safety and Effectiveness of Orphan Products; Availability of Grants; Request for Applications
Traduzione automatica locale · Lingua originale della fonte
Riepilogo
The Food and Drug Administration (FDA) is announcing changes to its Orphan Products Development (OPD) grant program for fiscal year (FY) 2002. This announcement supersedes the previous announcement of this program, which was published in the Federal Register of August 8, 2000.